Agenus gains after updating early-stage cancer drug data [Seeking Alpha]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Seeking Alpha
therapy, botensilimab plus balstilimab (BOT/BAL), developed in partnership with Ligand Pharmaceuticals ( NASDAQ: LGND The analysis was based on 77 patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) who had no active liver metastases (NLM). Citing NLM data, the company said that the drug combo led to an overall response rate (ORR) of 18%–33% and a disease control rate of 67%–82% in the patient population who had received a median of four prior lines of therapy. There were no new safety signals. Early this year, a March 1 data cut indicated that BOT/BAL led to an ORR of 23% following a median follow-up of 13.6 months. Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults [Yahoo! Finance]Yahoo! Finance
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for AdultsBusiness Wire
- Ligand to Participate in Upcoming Investor ConferencesBusiness Wire
- Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
LGND
Earnings
- 5/7/24 - Beat
LGND
Sec Filings
- 6/25/24 - Form 4
- 6/18/24 - Form 4
- 6/18/24 - Form 4
- LGND's page on the SEC website